Citigroup Upgrades agilon health (NYSE:AGL) to “Neutral”

Citigroup upgraded shares of agilon health (NYSE:AGL) from a sell rating to a neutral rating in a research note released on Friday, MarketBeat.com reports. The firm currently has $2.25 price objective on the stock, up from their prior price objective of $1.75.

AGL has been the topic of several other reports. Stifel Nicolaus decreased their price objective on agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a report on Tuesday, November 12th. Bank of America lowered shares of agilon health from a “buy” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research report on Wednesday, October 2nd. TD Cowen reduced their target price on shares of agilon health from $6.00 to $2.00 and set a “hold” rating on the stock in a report on Monday, November 11th. Needham & Company LLC began coverage on shares of agilon health in a report on Friday. They issued a “hold” rating for the company. Finally, Macquarie assumed coverage on agilon health in a research note on Monday, December 16th. They set a “neutral” rating and a $3.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.98.

agilon health Price Performance

Shares of NYSE:AGL opened at $2.42 on Friday. The firm has a market cap of $997.08 million, a price-to-earnings ratio of -2.57 and a beta of 0.53. The firm has a fifty day moving average price of $2.07 and a 200 day moving average price of $3.77. agilon health has a fifty-two week low of $1.50 and a fifty-two week high of $8.20. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.29 and a current ratio of 1.29.

agilon health (NYSE:AGL) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.19). agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. The company had revenue of $1.45 billion for the quarter, compared to the consensus estimate of $1.47 billion. During the same period last year, the company earned ($0.06) EPS. As a group, sell-side analysts expect that agilon health will post -0.52 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Diana Mckenzie purchased 12,500 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average price of $2.28 per share, for a total transaction of $28,500.00. Following the completion of the acquisition, the director now owns 51,319 shares of the company’s stock, valued at approximately $117,007.32. This trade represents a 32.20 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Karen Mcloughlin acquired 25,000 shares of agilon health stock in a transaction on Friday, December 13th. The shares were purchased at an average price of $2.20 per share, for a total transaction of $55,000.00. Following the completion of the acquisition, the director now directly owns 73,166 shares in the company, valued at $160,965.20. This trade represents a 51.90 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 90,000 shares of company stock valued at $198,100. 3.20% of the stock is currently owned by company insiders.

Institutional Trading of agilon health

A number of hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. boosted its position in agilon health by 2,251.5% during the 3rd quarter. Citigroup Inc. now owns 2,028,246 shares of the company’s stock valued at $7,971,000 after acquiring an additional 1,941,993 shares in the last quarter. AQR Capital Management LLC increased its holdings in agilon health by 3,338.5% in the 2nd quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock worth $8,871,000 after buying an additional 1,316,990 shares during the period. JPMorgan Chase & Co. raised its position in agilon health by 326.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,415,419 shares of the company’s stock worth $5,563,000 after buying an additional 1,083,492 shares during the last quarter. Quantbot Technologies LP acquired a new stake in agilon health during the 3rd quarter valued at approximately $1,742,000. Finally, Susquehanna Fundamental Investments LLC boosted its holdings in shares of agilon health by 65.0% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 804,594 shares of the company’s stock valued at $5,262,000 after acquiring an additional 316,856 shares during the last quarter.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.